Sesamoside

Synonyms: 胡麻属苷
Sesamoside 是一种可口服的抗炎、抗缺氧及镇痛剂,可抑制 ERK 和 JNK 磷酸化、下调 NLRP3 表达、限制 P65 的核定位、调控 AKR1B1 表达并降低脊髓中 TRPV1 基因的表达,同时减少 TNF-α、IL-6、IL-1β、iNOS 和 NO 的产生,恢复细胞代谢与器官功能,缓解冷觉及机械性痛觉过敏,可用于感染性休克、高原肺水肿及神经性疼痛的相关研究。
产品编号: MS-P71033 纯度: 99.77% CAS No.: 117479-87-5 分子式: C17H24O12 分子量: 420.37
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
10mM * 1mL in DMSO
询价
3-5 天
5mg
询价
3-5 天
10mg
询价
3-5 天
25mg
询价
3-5 天
50mg
询价
3-5 天
100mg
询价
3-5 天
200mg
询价
询价
500mg
询价
询价

产品描述

Sesamoside 是一种可口服的抗炎、抗缺氧及镇痛剂,可抑制 ERK 和 JNK 磷酸化、下调 NLRP3 表达、限制 P65 的核定位、调控 AKR1B1 表达并降低脊髓中 TRPV1 基因的表达,同时减少 TNF-α、IL-6、IL-1β、iNOS 和 NO 的产生,恢复细胞代谢与器官功能,缓解冷觉及机械性痛觉过敏,可用于感染性休克、高原肺水肿及神经性疼痛的相关研究。

生物实验数据

生物活性 Sesamoside is an orally available anti-inflammatory, anti-hypoxic, and analgesic agent that inhibits ERK and JNK phosphorylation, downregulates NLRP3 expression, restricts the nuclear localization of P65, modulates AKR1B1 expression, and reduces TRPV1 gene expression in the spinal cord, while decreasing the production of TNF-α, IL-6, IL-1β, iNOS, and NO, restoring cellular metabolism and organ function, and alleviating cold and mechanical hyperalgesia, and it can be used in research related to septic shock, high-altitude pulmonary edema, and neuropathic pain.
体外研究
(In Vitro)

Sesamoside (25-500 µM; 12 h) 对小鼠 Raw264.7 细胞的作用浓度高达 200 µM 时仍无细胞毒性,其 IC50 为 246.4 µM,仅在 500 µM 浓度下可诱导显著的细胞凋亡。
Sesamoside (25-200 µM; 6-24 h) 可呈剂量和时间依赖性抑制 LPS (MS-X54539) 诱导的小鼠 Raw264.7 细胞中 TNF-α、IL-6、IL-1β 及 iNOS mRNA 表达水平升高与 NO 生成。
Sesamoside (200 µM; 6-24 h) 可通过降低 ERK 和 JNK 的磷酸化水平,并以时间依赖的方式下调 NLRP3 蛋白表达,抑制 LPS 诱导的小鼠 Raw264.7 细胞中 NF-κB/MAPK 通路的激活。
Sesamoside (200 µM; 6-24 h) 可在 200 µM 浓度下以时间依赖的方式抑制 LPS 诱导的小鼠 Raw264.7 细胞中 P65 的核定位。
Sesamoside 可与人类醛糖还原酶 (AR/AKR1B1) 紧密结合,结合能为 -5.5 kcal/mol。
Sesamoside (200 μM; 6 h) 预处理人支气管上皮 BEAS-2B 细胞可显著降低缺氧诱导的 AR、ERK、VEGF-α 及 TNF-α mRNA 表达上调,升高缺氧下调的 IL-10 mRNA 表达,并减少缺氧诱导的 IL-6 分泌,但对 HIF-1α mRNA 表达无显著影响。
Sesamoside (200 μM; 6 h) 预处理人支气管上皮 BEAS-2B 细胞可减少缺氧诱导的 IL-6 分泌。

Cell Cytotoxicity Assay

Cell Line: mouse Raw264.7 macrophage cells
Concentration: 25, 50, 100, 200, 500 µM
Incubation Time: 12 h
Result: Showed almost no cytotoxicity at concentrations up to 200 µM, with an IC50 value of 246.4 µM.
Induced 31.61% apoptosis at 500 µM, while concentrations up to 200 µM caused negligible apoptosis.

Real Time qPCR

Cell Line: mouse Raw264.7 macrophage cells
Concentration: 25, 50, 100, 200 µM (6 h incubation); 200 µM (6, 12, 24 h incubation)
Incubation Time: 6 h (25-200 µM); 6, 12, 24 h (200 µM)
Result: Blocked LPS-induced increases in TNF-α, IL-6, IL-1β, and iNOS mRNA transcription at 25-200 µM for 6 h, with 200 µM showing the strongest effect.
Significantly inhibited mRNA transcription of all four targets and reduced NO production at 200 µM for 6, 12, or 24 h, with the inhibitory effect generally increasing with longer incubation times.

Western Blot Analysis

Cell Line: mouse Raw264.7 macrophage cells
Concentration: 200 µM
Incubation Time: 6, 12, 24 h
Result: Inhibited LPS-induced phosphorylation of ERK and JNK, and downregulated NLRP3 protein expression, with the inhibitory effect increasing in a time-dependent manner over 6-24 h.

Immunofluorescence

Cell Line: mouse Raw264.7 macrophage cells
Concentration: 200 µM
Incubation Time: 6, 12, 24 h
Result: Restricted LPS-induced nuclear translocation of P65 in a time-dependent manner, with the lowest nuclear P65 intensity observed after 24 h of treatment.

Real Time qPCR

Cell Line: human bronchial epithelial BEAS-2B cells
Concentration: 200 μM (pre-treatment); 800 μM (CoCl2, hypoxia induction)
Incubation Time: 6 h (pre-treatment); 6 h (hypoxia induction)
Result: Significantly reduced the hypoxia-induced upregulation of AR, ERK, and VEGF-α mRNA expression compared to the hypoxia-only group.
Significantly reduced the hypoxia-induced upregulation of TNF-α mRNA expression compared to the hypoxia-only group.
Significantly increased the hypoxia-downregulated IL-10 mRNA expression compared to the hypoxia-only group.
Partially reduced the upregulation of IL-6 mRNA expression compared to the hypoxia-only group, but the effect was not statistically significant.
Significantly reduced the hypoxia-induced increase in IL-6 concentration in cell supernatant compared to the hypoxia-only group.
Partially reduced TNF-α secretion compared to the hypoxia-only group, but the effect was not statistically significant.
Had no significant impact on hypoxia-downregulated HIF-1α mRNA expression compared to the hypoxia-only group.

ELISA Assay

Cell Line: human bronchial epithelial BEAS-2B cells
Concentration: 200 μM (pre-treatment); 800 μM (CoCl2, hypoxia induction)
Incubation Time: 6 h (pre-treatment); 6 h (hypoxia induction)
Result: Significantly reduced the hypoxia-induced increase in IL-6 concentration in cell supernatant compared to the hypoxia-only group.
Partially reduced TNF-α secretion compared to the hypoxia-only group, but the effect was not statistically significant.
体内研究
(In Vivo)

Sesamoside (1-10 mg/kg;腹腔注射;单次给药) 可通过抑制 NF-κB/MAPK 信号通路,剂量依赖性地减轻脓毒性休克小鼠中 LPS 诱导的炎症反应及多器官损伤。
Sesamoside (5-7.5 mg/kg;腹腔注射、口服;单次给药) 可缓解 Paclitaxel (HY-B0015) 诱导的小鼠冷觉及机械性周围神经病变,其中 7.5 mg/kg 剂量 (腹腔注射及口服) 均显示出稳定的药效,且口服 7.5 mg/kg Sesamoside 可降低小鼠脊髓 TRPV1 基因的表达水平。

Animal Model: Kunming mice (male, 8-10 weeks old, specific pathogen-free, intraperitoneal injection of 10 mg/kg LPS)
Dosage: 1 mg/kg; 5 mg/kg; 10 mg/kg
Administration: i.p.; single dose
Result: Significantly alleviated LPS-induced multi-organ damage to the heart, liver, spleen, lungs, and kidneys, reducing tissue congestion, edema, bleeding foci, and inflammatory cell infiltration in a dose-dependent manner.
Dose-dependently reduced mRNA transcription of pro-inflammatory cytokines TNF-α, IL-6, IL-1β, and iNOS in spleen tissue.
Inhibited LPS-induced phosphorylation of ERK and JNK, decreased protein expression of NLRP3 and P65 in spleen tissue.
Dose-dependently reduced nuclear localization of P65 in multiple organs.
Animal Model: C57BL/6 (male, 6-week-old, peripheral neuropathy induced by paclitaxel)
Dosage: 5 mg/kg; 7.5 mg/kg
Administration: i.p.; single dose; p.o.; single dose
Result: Significantly reduced cold hypersensitivity (decreased response frequency in acetone drop tests) and increased mechanical sensitivity threshold (increased 50% threshold value in von Frey filament tests) at 7.5 mg/kg i.p. compared to paclitaxel + PBS controls.
Showed no significant effect on cold or mechanical hypersensitivity at 5 mg/kg i.p. compared to paclitaxel + PBS controls.
Significantly reduced cold hypersensitivity at 5 mg/kg and 7.5 mg/kg p.o. compared to paclitaxel + PBS controls.
Significantly increased mechanical sensitivity threshold at 7.5 mg/kg p.o. compared to paclitaxel + PBS controls.
Showed no significant effect on mechanical sensitivity threshold at 5 mg/kg p.o. compared to paclitaxel + PBS controls.
Significantly downregulated spinal TRPV1 gene expression at 7.5 mg/kg p.o. compared to paclitaxel + PBS controls.
Showed no significant effect on spinal TRPV1 gene expression at 5 mg/kg p.o. compared to paclitaxel + PBS controls.
性状 固体
颜色 White to off-white

化学信息

分子量 420.37
分子式 C17H24O12
CAS No. 117479-87-5
别名 胡麻属苷

储存&溶解度

体内实验配方
10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (4.76 mM), Sonication is recommended.
请按顺序添加溶剂,在添加下一种溶剂之前,尽可能使溶液澄清。如有必要,可通过加热、超声、涡旋处理进行溶解。工作液建议现配现用。以上配方仅供参考,体内配方并不是绝对的,请根据不同情况进行调整。
储存方式

4°C, protect from light

*In solvent: -80°C, 6 months; -20°C, 1 month (protect from light)

运输条件 Room temperature in continental US; may vary elsewhere.
溶液配制表

DMSO 中的溶解度 : 100 mg/mL (237.89 mM; 超声助溶; 吸湿的 DMSO 对产品的溶解度有显著影响,请使用新开封的 DMSO)

可选溶剂浓度1 mg5 mg10 mg25 mg
DMSO1 mM2.3789 mL11.8943 mL23.7886 mL59.4714 mL
5 mM0.4758 mL2.3789 mL4.7577 mL11.8943 mL
10 mM0.2379 mL1.1894 mL2.3789 mL5.9471 mL
15 mM0.1586 mL0.7930 mL1.5859 mL3.9648 mL
20 mM0.1189 mL0.5947 mL1.1894 mL2.9736 mL
25 mM0.0952 mL0.4758 mL0.9515 mL2.3789 mL
30 mM0.0793 mL0.3965 mL0.7930 mL1.9824 mL
40 mM0.0595 mL0.2974 mL0.5947 mL1.4868 mL
50 mM0.0476 mL0.2379 mL0.4758 mL1.1894 mL
60 mM0.0396 mL0.1982 mL0.3965 mL0.9912 mL
80 mM0.0297 mL0.1487 mL0.2974 mL0.7434 mL
100 mM0.0238 mL0.1189 mL0.2379 mL0.5947 mL

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month (protect from light)。-80°C储存时,请在6个月内使用,-20°C储存时,请在1个月内使用。

该溶液配制表仅适用于固体产品。对于液体产品,请根据标明的浓度或密度计算稀释方案。

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础